Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
ConclusionsIn adjusted analyses, CCP+ patients with RA initiating treatment with abatacept versus tofacitinib did not show a statistically significant difference in reducing disease activity or improving patient-reported outcomes.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Abatacept | Arthritis | Orencia | Rheumatoid Arthritis | Rheumatology | Statistics | Study